Stock BIOS BIOSENIC SA
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases BioSenic SA

Equities

BIOS

BE0974280126

Market Closed - Euronext Bruxelles
Other stock markets
 11:35:11 2024-05-02 EDT 		5-day change 1st Jan Change
0.0142 EUR -4.05% Intraday chart for BioSenic SA -27.55% -76.80%
04-11 Biosenic: launch of a debt restructuring plan CF
03-12 Biosenic S.A. Releases Details of Optimized Administration Approach Ahead of Planned Phase 3 Trial of OATO for Chronic Graft-Versus-Host Disease CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BioSenic publishes on its website the restructuring plan submitted to the Enterprise Court of Nivelles
GL
BioSenic postpones its annual general meeting of the shareholders and provides temporary non-audited financial figures for 2023
GL
BioSenic postpones its annual general meeting of the shareholders and provides temporary non-audited financial figures for 2023
AQ
BioSenic S.A. : Transparency notifications received from François Rieger
GL
BioSenic provides further information on its restructuring plan
GL
BioSenic : summary bonds refinancing_20240411
PU
BioSenic and its restructuring practitioner (Me Yves Brulard) submit a global restructuring plan covering the years 2024-2030 to the Enterprise Court of Nivelles
GL
BioSenic and its restructuring practitioner (Me Yves Brulard) submit a global restructuring plan covering the years 2024-2030 to the Enterprise Court of Nivelles
AQ
BioSenic presents successful preclinical data on its ATO medication for controlling key symptoms at the 2024 Systemic Sclerosis World Congress
GL
BioSenic releases details of optimized administration approach ahead of planned Phase 3 trial of OATO for chronic graft-versus-host disease
GL
BioSenic raises €500,000 in private placement of new shares with established new investors
GL
BioSenic provides support to forthcoming European conference on graft-versus-host disease  
GL
BioSenic patent granted in Canada for broader protection of ATO therapeutic platform
GL
BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World Congress
GL
BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World Congress
AQ
BioSenic files for additional patent protection following new clinical evidence of efficacy for JTA-004 in osteoarthritis
GL
BioSenic S.A. : Transparency notifications received from François Rieger
GL
BioSenic reaches agreement on a binding term sheet with Phebra PTY Ltd. with respect to the development of the first oral formulation of arsenic troxide for cGvHD treatment
GL
BioSenic appoints Dr Carole Nicco as Chief Operating Officer in addition to Chief Scientific Officer
GL
BioSenic appoints Dr Carole Nicco as Chief Operating Officer in addition to Chief Scientific Officer
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BIOS Stock
  4. News BioSenic SA
  5. Press Releases